Particularly, intravitreal injections, using conventional hypodermic needles, of macromolecules such as anti-vascular endothelial growth factors (anti-VEGF) ranibizumab (Lucentis®, 48 k Da), bevacizumab (Avastin®, 149 k Da) and aflibercept (Eylea®, 97 kDa) are commonly practiced to treat posterior segment diseases (AMD) [11]. This evidence concerns the gene VEGFA and age-related macular degeneration.